Duchenne Muscular Dystrophy Survival Has Climbed From 19 to 29 Years, Landmark Analysis Shows

For most of modern medical history, a diagnosis of Duchenne muscular dystrophy carried a grim and predictable arithmetic. Boys born with the condition, caused by mutations in the dystrophin gene that strip muscle fibers of a crucial structural protein, were expected to lose the ability to walk in early adolescence and to die in their late teens or early twenties, usually suffocated by the gradual failure of the muscles that drive breathing. A new systematic review and cumulative meta-analysis, published in the Journal of Neurology, now quantifies just how dramatically that arithmetic has changed. Drawing on 53 studies and more than 13,000 patients, the analysis shows that median survival has climbed steadily across decades, from roughly 19 years in cohorts that did not include ventilated patients to nearly 29 years in cohorts where home mechanical ventilation became part of routine care.

The research team, led by Lara Benning and Esther Irene Schwarz of the University Hospital Zurich, registered the project on PROSPERO and followed the Meta-analyses Of Observational Studies in Epidemiology checklist. They searched PubMed from 1977 through late 2025, screened titles, abstracts and full texts with two independent reviewers, and applied strict inclusion criteria: studies had to involve individuals with Duchenne muscular dystrophy specifically, report appropriate survival data such as median survival or age at death, and be published in English. Cohorts published more than once contributed only their earliest and most comprehensive dataset. The final pool comprised 44 retrospective and 9 prospective studies, most conducted in Europe, North America and Asia, with a median follow-up of about eight years and a median patient age of just over 14 years.

Statistically, the challenge was considerable, because most studies reported median survival without confidence intervals or interquartile ranges. The authors therefore conducted a meta-analysis of means, first verifying that the underlying distributions showed negligible skewness so that medians could reasonably stand in for means. Standard errors were derived from interquartile ranges using the Wan and colleagues approximation, from 95 percent confidence intervals using the Cochrane Handbook formula, or imputed from sample-size-weighted median standard errors where nothing else was available. For studies that published only Kaplan-Meier survival curves, median survival was reconstructed using a method described by Broomfield and colleagues. Between-study heterogeneity was estimated with restricted maximum likelihood, confidence intervals were adjusted with the Hartung-Knapp method, and random-effects models weighted each study by inverse variance.

The headline numbers are striking. Across all included studies, pooled median survival was 23.9 years. But when the investigators split the evidence by ventilation status, a deep divide appeared. In the 16 studies that included no ventilated patients, pooled median survival was 19.0 years, with a 95 percent confidence interval of 18.2 to 19.7 years and moderate heterogeneity. In the 33 studies that included ventilated patients, pooled median survival reached 28.9 years, with a confidence interval of 27.0 to 30.7 years, though heterogeneity here was extreme, with an I-squared statistic of 98.2 percent. Meta-regression confirmed the pattern quantitatively: each percentage-point increase in the proportion of ventilated patients within a study was associated with a measurable gain in median survival, and ventilation status alone explained roughly 64 percent of the between-study variation.

Equally important is what the cumulative meta-analysis revealed about time itself. When studies were ordered chronologically and the pooled estimate was recalculated with each new addition, median survival rose progressively in both ventilated and non-ventilated cohorts. Stratified by era, median survival moved from 18.8 years in cohorts from around 1980 or earlier, to 22.2 years by around 1990, 25.1 years by around 2000, and 28 years by around 2010, holding at 27.1 years in the most recent period. The trajectory means that a boy diagnosed today, with access to comprehensive care, can reasonably expect to live into his late twenties or thirties, and some patients in well-resourced settings are now reported to survive into their forties and beyond.

The analysis also delivered a nuanced verdict on drug therapy. Glucocorticoids, the anti-inflammatory steroids long used to preserve ambulation and upper limb function in children with Duchenne muscular dystrophy, showed no significant association with survival in the meta-regression, whether or not the analysis was adjusted for study period. In contrast, heart failure medications emerged as powerful predictors of longevity. Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was significantly associated with longer median survival, explaining about 70 percent of between-study variation, and beta-blockers showed a similar association, though the authors caution that the beta-blocker finding rested on only six studies. All results remained consistent after adjustment for study period, and sensitivity analyses using alternative period classifications produced the same conclusions.

Perhaps the most consequential shift documented in the analysis concerns why patients die. In the earliest era, respiratory failure accounted for roughly 91.5 percent of deaths, the expected consequence of progressive diaphragm and intercostal muscle weakness. By the period around 1990, cardiac causes had risen to 57.1 percent of deaths, and in the most recent era other causes, including lower respiratory tract infections, gastrointestinal complications and adverse events related to anesthesia and surgery, contributed 45.7 percent. The overall median age at death climbed from 18.6 years in the earliest period to the mid-twenties in recent cohorts. In other words, ventilation has not merely extended life; it has rewritten the disease’s terminal chapter, transferring the burden of mortality from the lungs to the heart and to a widening spectrum of secondary complications.

That shift carries direct clinical implications. Progressive cardiomyopathy is now a major determinant of mortality, and a reduced left ventricular ejection fraction independently predicts earlier death, yet patients with Duchenne muscular dystrophy remain frequently undertreated for heart failure. Part of the problem is diagnostic: the standard New York Heart Association classification of heart failure relies on dyspnea and exercise intolerance, symptoms that skeletal muscle weakness confounds in non-ambulatory patients, so cardiac decline can be under-recognized until late. Current guidelines recommend starting ACE inhibitor or ARB therapy in late childhood, and prophylactic treatment has been linked to a survival benefit. The new meta-regression findings reinforce that recommendation, suggesting that early cardioprotective pharmacotherapy is one of the few modifiable factors clearly tied to longer life in this population.

The authors are candid about the limitations of their work. Assigning birth cohorts to periods was occasionally difficult because patients within single studies were born across wide intervals, and some studies had follow-up too short for death to occur or enrolled predominantly pediatric populations. Only about 38 percent of the pooled patients were deceased at the time of reporting, and mean age at death does not account for censoring. There is also the possibility of immortal-time bias in ventilated cohorts, since patients must survive long enough to receive ventilation. Incomplete reporting precluded detailed analyses of body mass index, glucocorticoid dosing, cough assist devices, scoliosis surgery and geographic variation, all of which may contribute to the pronounced heterogeneity. The team recommends that future studies report restricted mean survival time, the area under the Kaplan-Meier curve, as a more robust measure of average survival.

What emerges from the full picture is a disease transformed by systems of care rather than by any single drug. Non-invasive ventilation delivered through a nasal or facial mask, typically initiated around age twenty based on sleep studies and pulmonary function tests, marked the transformative step, and the analysis found no significant survival difference between non-invasive and invasive ventilation modalities, meaning patients can choose the approach that best preserves their quality of life. Forced vital capacity below one liter remains a strong negative predictor of mortality, and starting home ventilation slows the decline of lung function. But survival now depends equally on proactive cardiac surveillance, early heart failure management, and genuinely multidisciplinary teams spanning respiratory medicine, cardiology, neurology, rehabilitation, gastroenterology, nutrition, palliative care and mental health. Persistent disparities in outcomes across regions and healthcare systems suggest that the next frontier in Duchenne muscular dystrophy is not a molecule but equitable access to the care model that has already proven it can add a decade of life.

Subject of Research: Temporal trends in survival and causes of death in Duchenne muscular dystrophy

Article Title: Improving survival in Duchenne muscular dystrophy across eras: a systematic review and cumulative meta-analysis

Article References: Benning, L., Bousraou, Z., Gruber, B., Ulrich, S., & Schwarz, E. I. (2026). Improving survival in Duchenne muscular dystrophy across eras: a systematic review and cumulative meta-analysis. Journal of Neurology, 273(10), Article 564. https://doi.org/10.1007/s00415-026-14121-4

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14121-4

Keywords: Duchenne muscular dystrophy, survival, home mechanical ventilation, meta-analysis, cardiomyopathy, heart failure therapy, non-invasive ventilation, life expectancy, causes of death, glucocorticoids, dystrophin, multidisciplinary care